{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-005341","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.355994+00:00","generated_at":"2026-05-26T02:30:39.992140+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allarity Therapeutics announces dismissal of securities class action lawsuit against all defendants","bullets":["Securities class action filed Sept 13, 2024, alleging false statements on Dovitinib NDA prospects dismissed with prejudice.","No settlement or payment was made by the Company or officers in connection with dismissal.","CEO Thomas Jensen says dismissal allows focus on Phase 2 trial of stenoparib for advanced ovarian cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-005341","json":"https://secwatch.observer/filing/0001437749-25-005341.json","markdown":"https://secwatch.observer/filing/0001437749-25-005341.md","text":"https://secwatch.observer/filing/0001437749-25-005341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925005341/0001437749-25-005341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925005341/allr20250226_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:30:39.992140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}